News & Updates

Patients with diabetes mellitus are at reduced risk of developing open-angle glaucoma (OAG), although the magnitude of reduction is modest, according to a study.

Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.

There is inconclusive evidence that wearing one’s eyeglasses can lower their chances of contracting COVID-19, according to a recent study.

Drinking a lot of water does not seem to lower the risk of dry eye disease but may rather contribute to a modest risk increase, as reported in a recent cross-sectional study.

The single-dose nicotinic acetylcholine receptor agonist OC-02, administered as an aqueous nasal spray, helps increase tear production and improve eye dryness in patients with dry eye disease (DED), according to data from the phase II PEARL trial.